JAMJOOM PHARMACEUTICALS FACTORY COMPANY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 136.2 SAR | +2.41% |
|
-1.88% | +18.26% |
| 05-09 | Tadawul Shares Plunge Thursday as Saudi Arabia’s March Industrial Output Falls | MT |
| 05-09 | Jamjoom Pharmaceuticals Posts Higher Q1 Net Profit, Revenue | MT |
| Sales 2024 * | 1.27B 340M 27.03B | Sales 2025 * | 1.46B 388M 30.87B | Capitalization | 9.31B 2.48B 197B |
|---|---|---|---|---|---|
| Net income 2024 * | 312M 83.26M 6.62B | Net income 2025 * | 381M 102M 8.08B | EV / Sales 2024 * | 7.06 x |
| Net cash position 2024 * | 306M 81.7M 6.49B | Net cash position 2025 * | 415M 111M 8.8B | EV / Sales 2025 * | 6.11 x |
| P/E ratio 2024 * |
29.8
x | P/E ratio 2025 * |
24.4
x | Employees | - |
| Yield 2024 * |
2.21% | Yield 2025 * |
2.53% | Free-Float | 30% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.26% | ||
| 1 week | -1.88% | ||
| Current month | +4.78% | ||
| 1 month | +0.29% | ||
| 3 months | -7.73% | ||
| 6 months | +27.82% | ||
| Current year | +18.26% |
1 week
131.60
143.80
1 month
124.80143.80
Current year
112.80158.20
1 year
66.00158.20
3 years
66.00158.20
5 years
66.00158.20
10 years
66.00158.20
| Managers | Title | Age | Since |
|---|---|---|---|
Tarek Hosni
CEO | Chief Executive Officer | 60 | 14/05/21 |
Anwer Muhiddein
DFI | Director of Finance/CFO | 60 | 12/01/13 |
Mohammed Jamjoom
COO | Chief Operating Officer | 29 | 31/08/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Faris AlGhannam
BRD | Director/Board Member | - | 18/06/22 |
| Chairman | 64 | 18/06/22 | |
| Founder | 39 | 18/06/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/24 | 136.2 | +2.41% | 87 706 |
| 14/05/24 | 133 | -1.63% | 165,929 |
| 13/05/24 | 135.2 | -1.31% | 244,352 |
| 12/05/24 | 137 | -2.14% | 186,647 |
| 09/05/24 | 140 | +1.01% | 764,767 |
Delayed Quote Saudi Arabian S.E., May 15, 2024 at 10:11 am
More quotes
Jamjoom Pharmaceuticals Factory Company SJSC is a Saudi Arabia-based Company, which produces human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer and acidity, treatment of various skin infections, cancer diseases, eye drops and ointments and cosmeceuticals. The Company operates two segments, which include pharmaceutical products, that represents medicines or drugs, which all are essential for the prevention and treatment of diseases, and protection of public health; and Consumer health products segment that represents the products sold directly to consumers. The Companyâs subsidiaries include Al Jamjoom Pharma for Pharmaceutical Industries and Jamjoom Pharmaceutical Industry and Commerce Company Limited and the Company also operates approximately 8 branches.
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
133
SAR
Average target price
142.1
SAR
Spread / Average Target
+6.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.26% | 2.48B | |
| +21.32% | 44.4B | |
| +24.60% | 23.03B | |
| +17.04% | 15.14B | |
| +12.99% | 13.12B | |
| +44.77% | 11.85B | |
| -8.33% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.52B |
- Stock Market
- Equities
- 4015 Stock
